Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats

Immunopharmacology

Volumn 44, Issue 1-2, 1999, Pages 57-65

  Dobrzynski, Eric ^a   Yoshida, Hideaki ^a   Chao, Julie ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; DOCA salt hypertension; Kallikrein gene delivery; Renal protection

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; KALLIKREIN; TISSUE KALLIKREIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE TARGETING; GENE TRANSFER; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOVIRIDAE; ANIMALS; BODY WEIGHT; DESOXYCORTICOSTERONE; GENETIC VECTORS; HUMANS; HYPERTENSION; INJECTIONS, SUBCUTANEOUS; KIDNEY; MALE; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE; SYSTOLE; TISSUE KALLIKREINS; URINE;

EID: 0032741327     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00121-6     Document Type: Article

References (24)

1. Ader J.L., Tran-Van T., Praddaude F. Reduced urinary kallikrein activity in rats developing spontaneous hypertension. Am. J. Phys. 252:1987;F964-F969.
2. Berry T.D., Hasstedt S.J., Hunt S.C., Wu L.L., Smith J.B., Ash K.O., Kuida H., Williams R.R. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 13:1989;3-8.
3. Bhoola H.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1992;1-80.
4. Carretero O.A., Amin V.M., Ocholik T., Scicli A.G., Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to hypertensive effects of salt. A new radioimmunoassay for its direct determination. Circ. Res. 42:1978;727-731.
5. Chao J., Jin L., Chen L.M., Chen V., Chao L. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum. Gene Ther. 7:1996;901-911.
6. Chao J., Zhang J.J., Lin K.F., Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in dahl salt-sensitive rats. Hum. Gene Ther. 9:1998;21-31.
7. Cook N.R., Cohen J., Hebert P.R., Taylor J.O., Hennekens C.H. Implications of small reductions in diastolic blood pressure for primary prevention. Arch. Int. Med. 155:1955;701-709.
8. Gustafson G.T., Lerner U.H. Bradykinin stimulates bone resorption and lysosomal-enzyme release in cultured mouse calvaria. Biochem. J. 219:1984;329-332.
9. Horning B., Drexler H. Endothelial function and bradykinin in humans. Drugs. 54:1997;42-47.
10. Jooss K., Yang Y., Wilson J.M. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vector to mouse live and lung. Hum. Gene Ther. 7:1996;1555-1566.
11. Kaplan J.M., Smith A.E. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum. Gene Ther. 8:1997;1095-1104.
12. Madeddu P., Pinna Parpaglia P., Anania V., Glorioso N., Chao C., Wang C., Chao J. Sexual dimorphism of cardiovascular responses to early blockade of bradykinin receptors. Hypertension. 27:1996;746-751.
13. Margolius, H.S., Geller, R., Pisano, J.J., Sjoerdsma, A., 1971. Altered urinary kallikrein excretion in human hypertension. The LANCET, 1063-1065.
14. Murakami H., Yayama K., Chao L., Chao J. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 53:1998;1305-1313.
15. Nolly H., Carretero O.A., Lama M.C., Miatello R., Scili G. Vascular kallikrein in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 23:1994;185-188.
16. Pravenec M., Ken V., Kunes J., Scicli G., Carretero O.A., Simonet L.I. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension. 17:1991;242-246.
17. Schenk J., McNeill J.H. The pathogenesis of DOCA-salt hypertension. J. Pharmacol. Toxicol. Methods. 27:1992;161-170.
18. Uehara Y., Hirawa N., Kawabata Y., Suzuki T., Ohshima N., Oka K., Ikeda Y., Goto A., Toyo-oka T., Kizuki K., Omata M. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension. 24:1994;770-778.
19. Wang J., Xiong W., Yang Z., Davis T., Dewey M.J., Chao J., Chao L. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 23:1994;236-243.
20. Wang C., Chao L., Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 95:1995;1710-1716.
21. Wang D.Z., Chao L., Chao J. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 29:1997;488-493.
22. Woodley-Miller C., Chao J., Chao L. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J. Hypertens. 7:1989;865-871.
23. Yayama K., Wang C., Chao L., Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in goldblatt hypertensive rats. Hypertension. 31:1998;1104-1110.
24. Zinner S.H., Margolius H.S., Rosner B., Kass E.H. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation. 58:1978;908-915.